David Chairman, SVP of R&D at Valens Semiconductor Ltd., filed a Form 4 on November 12, 2026, reporting the exercise of stock options and sale of ordinary shares on November 10 and November 11, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: David Chairman, SVP of R&D at Valens Semiconductor Ltd. (NYSE:VLN)
  • Transactions covered: Two exercise-and-sale sequences on November 10, 2026 and November 11, 2026
  • Shares exercised and sold on November 10: 3,235 ordinary shares acquired via stock option exercise at $0.86 and sold at a weighted average price of $1.6635 (ranging from $1.66 to $1.6684)
  • Shares exercised and sold on November 11: 278 ordinary shares acquired via stock option exercise at $0.86 and sold at $1.66
  • Beneficial ownership following transactions: 403,968 ordinary shares held directly
  • Remaining derivative securities: 72,182 stock options (right to buy) with exercise price of $0.86, expiring June 9, 2031
  • Trading plan: Transactions were made pursuant to a Rule 10b5-1 trading plan adopted June 1, 2026

David Chairman's Option Exercises and Share Sales at Valens Semiconductor

According to the Form 4 filing, David Chairman, who serves as SVP of R&D at Valens Semiconductor Ltd., reported two sets of transactions across consecutive days. On November 10, 2026, the filing discloses that Chairman exercised 3,235 stock options at an exercise price of $0.86 per share, acquiring an equal number of ordinary shares, which were then sold on the same date. The filing notes the November 10 sale price was a weighted average of $1.6635, with individual transactions ranging from $1.66 to $1.6684. The reporting person undertook to provide full information regarding the number of shares sold at each separate price upon request, according to the filing.

On November 11, 2026, the filing reports an additional exercise of 278 stock options at the same $0.86 exercise price, with the resulting shares sold the same day at $1.66 per share. Following both sets of transactions, the filing states that Chairman held 403,968 ordinary shares directly, and his remaining stock options totaled 72,182, with an expiration date of June 9, 2031.

The filing states that all sales were effectuated pursuant to a Rule 10b5-1 trading plan that Chairman adopted on June 1, 2026. The form was signed by Meirav Shemesh on behalf of Oppenheimer Israel, as attorney-in-fact, and filed on November 12, 2026. The options exercised were originally exercisable as of June 1, 2022.

What Was Disclosed

Valens Semiconductor SVP of R&D David Chairman reported the exercise of a total of 3,513 stock options and the same-day sale of the resulting ordinary shares on November 10 and November 11, 2026, under a pre-established Rule 10b5-1 plan, leaving him with 403,968 directly held shares.